|
 |
Prostate Cancer > Phase Ii Trial
The following information is about Phase Ii Trial.
Phase Ii Trial Defined
A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.
This definition is in context to Prostate Cancer. See more contextual defintions for Phase Ii Trial.
Immunomedics Announces Outcome of 2008 Annual Meeting of Stockholders
Published December 3, 2008, 8:33 am, GlobeNewswire via Yahoo! Finance
MORRIS PLAINS, N.J., Dec. 3, 2008 -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that stockholders of the Company, at its 25th annual meeting, elected all seven nominees to serve as directors of the Company until the next annual meeting, and ratified the selection of Ernst & Young LLP as ...
Updated Pictures of CEL-SCI Manufacturing Facility Available Online
Published December 3, 2008, 6:45 am, PR Newswire via Yahoo! Finance
In response to numerous shareholder inquiries, CEL-SCI Corporation announced today that it has added updated pictures of it new manufacturing facility to its website. The pictures can be accessed through CEL-SCI's homepage by clicking on the link "Updated Pictures of Manufacturing Facility" in the special highlights section.
Biocompatibles Press Announcement
Published December 3, 2008, 5:14 am, Medical News Today
Biocompatibles International plc is pleased to announce that The International Neuroscience Institute (INI), Hannover today held a press conference which covered the following: - Milestone in Medical Treatment - First ever Treatment of Stroke Patient with Stem Cell Therapy Product - Internati
Geron Announces Initiation of Phase I Clinical Trial of Vaccine Candidate Targeting Telomerase by Merck & Co., Inc.
Published December 3, 2008, 4:47 am, Centre Daily Times
Geron Corporation (Nasdaq:GERN) announced today that its collaborator, Merck & Co., Inc., has initiated a Phase I clinical trial of V934/V935, a non-dendritic cell based cancer vaccine candidate targeting telomerase. The trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in patients with solid tumors, including non-small cell lung cancer and prostate ...
Geron Announces Initiation of Phase I Clinical Trial of Vaccine Candidate Targeting Telomerase by Merck & Co., Inc.
Published December 3, 2008, 4:30 am, Business Wire via Yahoo! Finance
MENLO PARK, Calif.----Geron Corporation announced today that its collaborator, Merck & Co., Inc., has initiated a Phase I clinical trial of V934/V935, a non-dendritic cell based cancer vaccine candidate targeting telomerase.
Phase II Study Shows That ZD4054 Could Improve Survival For Hormone Resistant Prostate Cancer (HRPC) Patients With ...
Published December 3, 2008, 4:10 am, Medical News Today
A novel compound in development by AstraZeneca as an oral tablet for hormone resistant prostate cancer (HRPC), ZD4054, could improve overall survival (OS) in men with metastatic HRPC, according to Phase II data published today in European Urology.
Ark files marketing authorization application for cancer drug
Published December 3, 2008, 2:54 am, Pharmaceutical Business Review
Ark Therapeutics Group, a healthcare group, has filed the marketing authorization application for Cerepro, the companys novel gene-based therapy for operable malignant glioma, with the European medicines regulatory agency.
Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study In Platinum-Resistant Ovarian Cancer
Published December 2, 2008, 6:35 am, Centre Daily Times
Morphotek ® , Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of farletuzumab (also known as MORAb-003). The study will evaluate farletuzumab, plus the chemotherapy drug paclitaxel, in patients with platinum-resistant (PR) ovarian cancer. The randomized, controlled trial will compare farletuzumab plus paclitaxel with ...
Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting ...
Published December 2, 2008, 6:27 am, PR Newswire via Yahoo! Finance
176b in Atrial Fibrillation Included in Scientific Program
Ark Files Cerepro(R) Application For Marketing Authorisation With EMEA
Published December 2, 2008, 6:12 am, Medical News Today
Ark Therapeutics Group plc (AKT: LSE) ("Ark" or "the Company") today announces that the Marketing Authorisation Application (MAA) for Cerepro®, Ark's novel gene-based therapy for operable malignant glioma (brain cancer), has been filed with the European medicines regulatory agency (EMEA).
Are you looking for additional Prostate Cancer > Phase Ii Trial news? Try our new "Phase Ii Trial News Focus" area.
Social bookmarks are not available at the moment.
If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Phase Ii Trial. If you would like to find related tags we recommend Tag Patterns > Phase Ii Trial
Off-site Phase Ii Trial Research Links
If you still need additional information on Phase Ii Trial then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
- A9 > Phase Ii Trial
- Alexa > Phase Ii Trial
- Anti-Aging Revolution > Phase Ii Trial
- DMOZ > Phase Ii Trial
- Feeds Filtered > Phase Ii Trial
- Google > Phase Ii Trial
- News Meme > Phase Ii Trial
- Nuah: News > Phase Ii Trial
- The Feed Directory > Phase Ii Trial
- OBP > Phase Ii Trial
- Open Tag Directory > Phase Ii Trial
- Podzy > Phase Ii Trial
- Yahoo > Phase Ii Trial
Prostate Cancer Topics
Everything you need to know about Prostate Cancer
Prostate Cancer
If you know the Prostate Cancer Term Name use the links below to quickly jump to your desired focus.
Bookmark Us
The On Topic Network
This website is part of The On Topic Network.
Thank You
Prostate-Cancer.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.
Best Viewed With
License
This work is licensed under Creative Commons.